<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399100</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1756-2856</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Therapeutic advances in neurological disorders</Title><ISOAbbreviation>Ther Adv Neurol Disord</ISOAbbreviation></Journal><ArticleTitle>Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.</ArticleTitle><Pagination><StartPage>17562864241277736</StartPage><MedlinePgn>17562864241277736</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17562864241277736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/17562864241277736</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Patients with multiple sclerosis (PwMS) have an increased risk of infections.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To characterize incidence, clinical characteristics, outcomes and risk factors of infections, and serious infections (SIs) in ocrelizumab (OCR)-treated PwMS.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED"><i>Post-hoc</i> analysis of pooled data from 6155 patients in 13 clinical trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Descriptive analyses of clinical characteristics and outcomes were reported over ⩽14 years. A Poisson Generalized Estimating Equation model was constructed to examine risk factors in a subgroup of patients with longer exposure to OCR (<i>n</i> = 2092).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Over a median (max) treatment period of 3.7 (13.9) years, 420/6155 patients (6.8%) experienced 583 SIs, excluding coronavirus disease 2019. Incidence rates in relapsing multiple sclerosis (RMS; 1.50 per 100 patient years [95% confidence interval (CI): 1.34-1.68]) and progressive multiple sclerosis (PMS; 3.70 [95% CI: 3.27-4.17]) remained stable over this period. Lower respiratory tract, urinary tract, abdominal and gastrointestinal, and skin infections were the most commonly reported SIs. Most SIs (~90%) resolved, and treatment with OCR was continued in &gt;80% of cases. The presence of 1 or ⩾2 comorbidities (rate ratio = 1.66, 2.73, respectively), recent relapse activity (2.06), and Expanded Disability Status Scale (EDSS) score ⩾6.0 (2.02) were significant risk factors for SIs in patients with RMS treated over a median (max) period of 8.3 (11.2) years. In patients with primary PMS treated over a median (max) period of 7.1 (11.8) years, an EDSS score ⩾6.0 was associated with the greatest risk of SIs, a 4-fold increase (rate ratio, 4.31), followed by abnormal immunoglobulin (Ig)M levels (1.89), the presence of ⩾2 comorbidities (1.80), and having overweight/obesity (1.46). Time on OCR and abnormal IgG levels were not significantly associated with an increased SI risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Continuous long-term treatment with OCR is associated with a manageable infection risk profile. Optimal disease control and addressing modifiable risk factors may reduce the risk of infections.</AbstractText><CopyrightInformation>© The Author(s), 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Derfuss</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8656-4250</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Basel, University of Basel, Hebelstrasse 20, Basel 4031, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermel</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2334-6883</Identifier><AffiliationInfo><Affiliation>Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chien-Ju</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kappos</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4175-5509</Identifier><AffiliationInfo><Affiliation>Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollmer</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giovannoni</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartung</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0002-0614-6989</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UKD, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Centre, Göttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianmei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessop</LastName><ForeName>Nikki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chognot</LastName><ForeName>Cathy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craveiro</LastName><ForeName>Licinio</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8841-8035</Identifier><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-Or</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Neurol Disord</MedlineTA><NlmUniqueID>101480242</NlmUniqueID><ISSNLinking>1756-2856</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Is continued treatment with ocrelizumab associated with a higher risk of infections and serious infections in patients with multiple sclerosis? Patients with multiple sclerosis (PwMS) are at an increased risk of infections compared with the general population. Infections are also among the most frequently reported side effect in PwMS treated with ocrelizumab. Initial analyses have shown that serious infection (SI) rates in PwMS treated with ocrelizumab were stable over 6 years, but there is concern that this rate may increase with continued treatment. This study aimed to describe infections and SIs in PwMS treated with ocrelizumab and look into factors that increase patients’ susceptibility to infections. We analyzed the largest population of PwMS ever treated with ocrelizumab, including 6155 patients from 13 clinical trials. Some of these patients received ocrelizumab for as long as 14 years. Approximately 7 out of every 100 patients experienced SIs, excluding COVID-19 infections, with no increase in yearly rates of SIs over time. Pneumonia and urinary tract infections were the most common SIs. Almost all patients recovered from their infections (&gt;9 out of 10 cases), and continued treatment with ocrelizumab (&gt;8 out of 10 cases). When looking at factors that made PwMS more prone to SIs, we found that patients with relapsing MS had an increased risk if they had experienced recent MS relapses, severe walking difficulties, or other health conditions like diabetes and bladder problems. Patients with primary progressive MS (PPMS) with severe walking difficulties were four times more likely to have SIs. Having other health conditions like heart or bladder problems, low levels of immunoglobulin M, or excess weight also increased the risk of SIs in patients with PPMS. In conclusion, continued treatment with ocrelizumab did not increase the risk of SIs, and most of those infections resolved without stopping ocrelizumab treatment. Addressing certain health conditions and achieving a good control of the MS disease may help to reduce the risk of SIs.</AbstractText><CopyrightInformation>© The Author(s), 2024.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">disease-modifying therapies</Keyword><Keyword MajorTopicYN="N">infections</Keyword><Keyword MajorTopicYN="N">long-term data</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">serious infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399100</ArticleId><ArticleId IdType="pmc">PMC11470513</ArticleId><ArticleId IdType="doi">10.1177/17562864241277736</ArticleId><ArticleId IdType="pii">10.1177_17562864241277736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijnands JM, Kingwell E, Zhu F, et al.. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 2017; 23: 1506–1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">28273769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnands JMA, Zhu F, Kingwell E, et al.. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 2018; 89: 1050–1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">29602795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RE, Xie Y, DuVall SL, et al.. Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care 2015; 17: 221–230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599359</ArticleId><ArticleId IdType="pubmed">26472943</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson R, Lee S, Ulcickas Yood M, et al.. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord 2020; 41: 101982.</Citation><ArticleIdList><ArticleId IdType="pubmed">32070858</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 2013; 20: 1153–1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">23496086</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo-Branco A, Chiesa F, Conte S, et al.. Infections in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler Relat Disord 2020; 45: 102420.</Citation><ArticleIdList><ArticleId IdType="pubmed">32736217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick SS, Li L, Falcone GJ, et al.. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol 2015; 262: 2033–2041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768220</ArticleId><ArticleId IdType="pubmed">26067217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell E, Zhu F, Evans C, et al.. Causes that contribute to the excess mortality risk in multiple sclerosis: a population-based study. Neuroepidemiology 2020; 54: 131–139.</Citation><ArticleIdList><ArticleId IdType="pubmed">31852000</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding K, Zhu F, Alotaibi M, et al.. Multiple cause of death analysis in multiple sclerosis: a population-based study. Neurology 2020; 94: e820–e829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136054</ArticleId><ArticleId IdType="pubmed">31932517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Kappos L, Montalban X, et al.. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology 2021; 97: e1546–e1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548959</ArticleId><ArticleId IdType="pubmed">34475123</ArticleId></ArticleIdList></Reference><Reference><Citation>
Genentech Inc.
OCREVUS (ocrelizumab). Prescribing information, https://www.gene.com/download/pdf/ocrevus_prescribing.pdf (2024, accessed 10 May 2024).</Citation></Reference><Reference><Citation>
Genentech Inc.
RITUXAN (rituximab). Prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5464lbl.pdf (2021, accessed 10 May 2024).</Citation></Reference><Reference><Citation>
Novartis Inc. KESIMPTA (ofatumumab). Prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf (2020, accessed 10 May 2024).</Citation></Reference><Reference><Citation>
TG Therapeutics. BRIUMVI (ublituximab). Prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf (2022, accessed 10 May 2024).</Citation></Reference><Reference><Citation>
European Centre for Disease Prevention and Control. Case definition for COVID-19, https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition (2020, accessed 20 October 2021).</Citation></Reference><Reference><Citation>
U.S.
Food &amp; Drug Administration. What is a serious adverse event?, https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event (2016, accessed 9 August 2022).</Citation></Reference><Reference><Citation>
National Cancer Institute. Common terminology criteria for adverse events (CTCAE), https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf (2017, accessed 29 October 2021).</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, et al.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser A, Steiner C, Harris DR, et al.. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ 2016; 352: i1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">27121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolini LA, Canepa P, Caligiuri P, et al.. Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis. JAMA Neurol 2019; 76: 866–867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583842</ArticleId><ArticleId IdType="pubmed">30958517</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp R, Hardstock F, Kreiger J, et al.. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: a German claims data study. Mult Scler Relat Disord 2022; 68: 104257.</Citation><ArticleIdList><ArticleId IdType="pubmed">36306609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Cross AH, Winthrop K, et al.. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler 2022; 28: 1576–1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330270</ArticleId><ArticleId IdType="pubmed">35229668</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmer BL, Wallach AI, Corboy JR, et al.. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020; 7: 1477–1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480911</ArticleId><ArticleId IdType="pubmed">32767531</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson NW, Goodwin RD, Okkels N, et al.. Depression and the risk of severe infections: prospective analyses on a nationwide representative sample. Int J Epidemiol 2016; 45: 131–139.</Citation><ArticleIdList><ArticleId IdType="pubmed">26708840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobner J, Kaser S. Body mass index and the risk of infection—from underweight to obesity. Clin Microbiol Infect 2018; 24: 24–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">28232162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky JS, Arnold DL, Brochet B, et al.. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2020; 19: 998–1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">33129442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Kappos L, Arnold DL, et al.. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 2020; 95: e1854–e1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682822</ArticleId><ArticleId IdType="pubmed">32690791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycett M, Lea R, Maltby V, et al.. The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis. Mult Scler J Exp Transl Clin 2023; 9: 20552173221149688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830094</ArticleId><ArticleId IdType="pubmed">36636583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoehner G, Miclea A, Salmen A, et al.. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord 2019; 12: 1756286419878340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6767745</ArticleId><ArticleId IdType="pubmed">31632461</ArticleId></ArticleIdList></Reference><Reference><Citation>Selter R, Biberacher V, Grummel V, et al.. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler 2013; 19: 1454–1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo G, Kappos L, Cross A, et al.. Ofatumumab reduces clinical and radiological activity in people with recently diagnosed treatment-naive relapsing multiple sclerosis irrespective of baseline serum neurofilament light chain levels. Poster P9.008 presented at the 76th American Academy of Neurology (AAN) Annual Meeting, 13–18 April 2024, Denver, CO, USA.</Citation></Reference><Reference><Citation>European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370–398.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427875</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonomo AR, Viceconte G, Calabrese M, et al.. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 2022; 269: 3301–3307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119877</ArticleId><ArticleId IdType="pubmed">35165767</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmann A, Loebermann M, Reisinger EC, et al.. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12: 217–233.</Citation><ArticleIdList><ArticleId IdType="pubmed">26943779</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotto R, Reia A, Buonomo AR, et al.. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. Expert Opin Drug Saf 2021; 20: 925–936.</Citation><ArticleIdList><ArticleId IdType="pubmed">33880975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray S, Havrdova E, Snydman DR, et al.. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler 2019; 25: 1605–1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764150</ArticleId><ArticleId IdType="pubmed">30289355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab N, Schneider-Hohendorf T, Melzer N, et al.. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88: 1197–1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">28228564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourcher V. What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Rev Neurol (Paris) 2020; 176: 235–243.</Citation><ArticleIdList><ArticleId IdType="pubmed">31983473</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Thomas K, Hatch R, et al.. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis 2021; 21: 1518–1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219489</ArticleId><ArticleId IdType="pubmed">34171232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R, Whitley L, Fitovski K, et al.. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 2021; 49: 102725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772086</ArticleId><ArticleId IdType="pubmed">33482590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Gold R, Cutter G, et al.. COVID-19 in people with multiple sclerosis treated with ocrelizumab. Poster P933 presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13–15 October 2021, Virtual Congress.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>